Biography
Biography: Maryam Borumand
Abstract
Since its establishment in 2004, GENOSS has put enormous efforts to become the world’s leading medical device company. The primary mission set forth by GENOSS is to focus on delivering treatment solutions and promoting the well-being of its consumers and patients. GENOSS strives to prepare for a big leap forward into the endless competition of the world’s biotechnology market through its technical innovation. With a considerable portion of sales being spent on Research & Development, and supported by a group of immensely experienced and talented R&D professionals, GENOSS has demonstrated a strong commitment to R&D and to manufacture products with world-beating quality. In addition, GENOSS strictly fulfills and complies with the international quality regulations, including KGMP, ISO 13485 and ISO 9001. Furthermore, the CE mark and the FDA approval on each product confirm its conformity with all of the legal requirements. Mona Lisa dermal filler is new innovative filler with the following properties: 1. Volume effect and retention - the uniform sized hyaluronic acid particles with optimal viscoelasticity can maintain a long-lasting volume. 2. Safe to use on patients – Mona Lisa is safe to use on patients due to low level of endotoxin and essentially no BDDE residue. 3. Easy procedural operation - the ergonomically-designed rod and grip allow the even distribution of pressure during injection to enable an accurate and safe treatment for both the clinician and the patient. 4. Highly pure hyaluronic acid-GENOSS implements a strict quality control system through direct involvement in the entire production process from the base material of hyaluronic acid to the final product. 5. Global standard quality control - To guarantee the quality of Mona Lisa, GENOSS strictly fulfills and complies with the international quality regulations, including KGMP, ISO 13485 and ISO 9001